SLC5A2 and diabetes mellitus: The beneficial effect on organ protection observed in these studies demonstrates a notable advantage for phytocannabinoids over conventional synthetic SGLT2 inhibitors in treating diabetes-related complications, such as chronic inflammation, chronic oxidative stress, and CVD.